FDA
-
-
-
-
-
-
-
These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
-
-
-
-
-
-
-
NeOnc phase 2a trial of intranasal NEO100 meets primary endpoint
-
-
-
-
-
-
-
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
-
-
-
-
-
-
-
NeOnc gets FDA manufacturing feedback for NEO212 tablet transition
-
-
-
-
-
-
-
International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
-
-
-
-
-
-
-
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
-
-
-
-
-
-
-
NeOnc Technologies names David Choi as chief accounting officer
-
330,185 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

